Business Context and Reporting Period
This Form 8-K was filed by OncoCyte Corporation (trading symbol: OCX) on March 20, 2020. The report details the entry into a material definitive agreement to establish an at-the-market equity distribution program.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The primary financial metric disclosed is the authorization to sell up to $25,000,000 of common stock through the new program.
Material Changes
- Equity Distribution Agreement: On March 20, 2020, the Company entered into an agreement with Piper Sandler & Co. to sell shares via an at-the-market (ATM) offering.
- Commission Structure: The Company will pay the Agent a commission of up to 3.0% of the gross proceeds from any shares sold.
- Flexibility: The Company retains the right to set sales parameters, including timing and price floors, and has no obligation to sell any shares. Offers can be suspended at any time.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on operational outlook, or specific risk factors beyond standard legal disclaimers. The primary contingency is the potential dilution of existing shareholders should the Company elect to sell shares under the ATM program. The shares are issued pursuant to a previously effective Form S-3 Registration Statement.
Investor Verification Checklist
- Verify the current market price of OCX common stock to assess potential dilution impact.
- Review the full text of the Equity Distribution Agreement (Exhibit 10.1) for specific termination provisions and sales limitations.
- Check subsequent filings to determine if and when the Company has executed sales under this ATM program.
- Confirm the Company's current cash position to understand the necessity of this financing option.